Trials / Recruiting
RecruitingNCT07483294
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Northwell Health · Academic / Other
- Sex
- All
- Age
- 16 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A total of 120 patients diagnosed with a first-episode psychotic disorder will be recruited. All subjects receive naturalistic treatment with either risperidone or aripiprazole for 12 weeks, with dosage and titration followed by standard clinical care. A comprehensive clinical and neuroimaging assessments will be performed before and after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risperidone | Naturalistic treatment |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2029-12-01
- Completion
- 2030-06-01
- First posted
- 2026-03-19
- Last updated
- 2026-04-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07483294. Inclusion in this directory is not an endorsement.